Clinical Research Directory

Inclusion Criteria: * Among hemodialysis patients with secondary hyperparathyroidism due to chronic kidney disease (CKD 5D), those who are scheduled to administer Pacitol Inj. according to the product information. * Those who voluntarily signed a written personal information collection and usage agreement to participate in this clinical study after receiving an explanation about the objective and methods of the study. * Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion. Exclusion Criteria: * Those with a history of hypersensitivity reactions to this drug or its components * Those with evidence of vitamin D toxicity * Those with hypercalcemia at enrollment * Pregnant or lactating women * Those with evidence of parathyroid adenoma who is scheduled to undergo parathyroidectomy. * Those who have been administered with investigational drugs of other clinical trials within 12 weeks from the baseline(Visit 1). * Those who are judged by the principle Investigator or sub-Investigator to be ineligible to participate in the study.